RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup

Launch of City Therapeutics:
A new biotech startup, City Therapeutics, has been launched by a team of former Alnylam executives, including John Maraganore, with a focus on developing next-generation RNA interference (RNAi) medicines.

Funding:
The startup has secured $135 million in funding to support its mission of building the future of RNAi therapies.

Background:
Alnylam Pharmaceuticals is a pioneer in RNAi technology, and the new startup aims to leverage this expertise to create advanced siRNA engineering capabilities.

Objective:
City Therapeutics plans to develop innovative RNAi medicines that can target a wide range of diseases, leveraging the potential of siRNA engineering to improve therapeutic outcomes.

Leadership:
John Maraganore, a former CEO of Alnylam, leads City Therapeutics, bringing extensive experience in RNAi technology and biotech leadership to the new venture.